Compare Stocks → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BFRINASDAQ:GRTXNASDAQ:ITRMNASDAQ:LRMRNASDAQ:NLTX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFRIBiofrontera$1.66+10.7%$1.37$0.61▼$13.42$8.45M0.83646,464 shs62,560 shsGRTXGalera Therapeutics$0.18-5.2%$0.20$0.09▼$3.59$9.94M2.172.37 million shs814,562 shsITRMIterum Therapeutics$1.55-1.9%$1.51$0.62▼$2.50$25.47M2.36507,395 shs35,939 shsLRMRLarimar Therapeutics$6.46$9.01$2.18▼$13.68$412.15M0.93557,455 shs222,439 shsNLTXNeoleukin Therapeutics$30.23-3.0%$37.24$2.03▼$14.36$284.10M1.1150,104 shs52,572 shsThe Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFRIBiofrontera+10.67%-2.92%+40.68%+12.16%-85.97%GRTXGalera Therapeutics-5.82%-7.91%-18.44%+5.00%-93.36%ITRMIterum Therapeutics-1.90%+7.64%0.00%-6.63%+51.22%LRMRLarimar Therapeutics0.00%-8.37%-14.78%+36.58%+43.24%NLTXNeoleukin Therapeutics0.00%-11.45%-36.43%+3.90%+84.46%top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBFRIBiofrontera2.4292 of 5 stars3.55.00.00.01.10.01.3GRTXGalera TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AITRMIterum Therapeutics0.8695 of 5 stars3.52.00.00.00.60.00.6LRMRLarimar Therapeutics2.1757 of 5 stars4.51.00.00.00.63.30.0NLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBFRIBiofrontera3.00Buy$18.00984.34% UpsideGRTXGalera Therapeutics1.75ReduceN/AN/AITRMIterum Therapeutics3.00Buy$6.00287.10% UpsideLRMRLarimar Therapeutics3.00Buy$18.50186.38% UpsideNLTXNeoleukin TherapeuticsN/AN/A$30.00-0.76% DownsideCurrent Analyst RatingsLatest LRMR, ITRM, GRTX, BFRI, and NLTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/3/2024LRMRLarimar TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform4/3/2024LRMRLarimar TherapeuticsSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$25.004/1/2024ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.003/15/2024LRMRLarimar TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$25.003/6/2024ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.002/20/2024LRMRLarimar TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform2/13/2024LRMRLarimar TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.50 ➝ $10.002/13/2024LRMRLarimar TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$17.00 ➝ $25.002/7/2024ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$6.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBFRIBiofrontera$34.07M0.25N/AN/A$3.16 per share0.53GRTXGalera TherapeuticsN/AN/AN/AN/A($2.41) per shareN/AITRMIterum TherapeuticsN/AN/AN/AN/A($0.48) per shareN/ALRMRLarimar TherapeuticsN/AN/AN/AN/A$1.86 per shareN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/A$11.08 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBFRIBiofrontera-$20.13M-$15.82N/AN/AN/A-59.09%-344.98%-72.85%5/10/2024 (Estimated)GRTXGalera Therapeutics-$59.08M-$1.41N/A∞N/AN/AN/A-137.47%5/9/2024 (Estimated)ITRMIterum Therapeutics-$38.37M-$2.97N/AN/AN/AN/A-664.00%-87.64%5/10/2024 (Estimated)LRMRLarimar Therapeutics-$36.95M-$0.85N/AN/AN/AN/A-38.83%-34.33%5/20/2024 (Estimated)NLTXNeoleukin Therapeutics-$57.56M-$3.11N/A∞N/AN/A-37.22%-30.91%N/ALatest LRMR, ITRM, GRTX, BFRI, and NLTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023GRTXGalera TherapeuticsN/A-$0.10-$0.10-$0.10N/AN/A3/28/2024Q4 2023ITRMIterum Therapeutics-$1.02-$0.94+$0.08-$0.94N/AN/A3/15/2024Q4 2023BFRIBiofronteraN/A-$2.33-$2.33-$6.31N/A$10.60 million3/14/2024Q4 2023LRMRLarimar Therapeutics-$0.25-$0.30-$0.05-$0.30N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBFRIBiofronteraN/AN/AN/AN/AN/AGRTXGalera TherapeuticsN/AN/AN/AN/AN/AITRMIterum TherapeuticsN/AN/AN/AN/AN/ALRMRLarimar TherapeuticsN/AN/AN/AN/AN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBFRIBiofronteraN/A1.280.67GRTXGalera TherapeuticsN/A4.364.36ITRMIterum Therapeutics3.631.891.89LRMRLarimar TherapeuticsN/A9.499.49NLTXNeoleukin TherapeuticsN/A15.3315.33OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBFRIBiofrontera10.08%GRTXGalera Therapeutics50.77%ITRMIterum Therapeutics9.21%LRMRLarimar Therapeutics91.92%NLTXNeoleukin Therapeutics52.37%Insider OwnershipCompanyInsider OwnershipBFRIBiofrontera0.21%GRTXGalera Therapeutics6.90%ITRMIterum Therapeutics5.40%LRMRLarimar Therapeutics4.30%NLTXNeoleukin Therapeutics1.58%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBFRIBiofrontera835.09 million5.08 millionNo DataGRTXGalera Therapeutics754.39 million50.64 millionOptionableITRMIterum Therapeutics1416.43 million15.54 millionNot OptionableLRMRLarimar Therapeutics4263.80 million61.06 millionOptionableNLTXNeoleukin Therapeutics79.40 million9.25 millionOptionableLRMR, ITRM, GRTX, BFRI, and NLTX HeadlinesSourceHeadlineNeurogene concludes merger deal with Neoleukin Therapeuticspharmaceutical-technology.com - December 20 at 9:16 AMIs Neoleukin Therapeutics (NASDAQ:NLTX) In A Good Position To Invest In Growth?finance.yahoo.com - December 20 at 9:16 AMNeoleukin Therapeutics Announces 1-for-4 Reverse Stock Splitfinance.yahoo.com - December 15 at 12:06 AMNeoleukin Therapeutics Stock (NASDAQ:NLTX) Dividends: History, Yield and Datesbenzinga.com - December 4 at 11:08 PMPre-market Movers: ORTX, CMBM, GROM, RSVR, FEMY…markets.businessinsider.com - October 5 at 8:10 AMNeoleukin Therapeutics, Inc.: Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Splitfinanznachrichten.de - September 26 at 8:11 AMNeoleukin Thera (NASDAQ: NLTX) should be up 500% - it’s actually up 7%dhakatribune.com - September 26 at 8:11 AMNeoleukin Therapeutics Announces 1-for-5 Reverse Stock Splitfinance.yahoo.com - September 22 at 8:21 AMInvesting in Neoleukin Therapeutics Inc. [NLTX]: What You Must Knowknoxdaily.com - August 21 at 5:51 PMNeoleukin Therapeutics Recent Insider Activitybenzinga.com - August 18 at 4:56 PMBAKER BROS. ADVISORS LP Reduces Stake in Neoleukin Therapeutics Incfinance.yahoo.com - August 18 at 4:56 PMSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMNB, CCF, NLTX, SCUmarkets.businessinsider.com - August 8 at 8:05 AMSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AJX, DEN, FREQ, NLTXmarkets.businessinsider.com - August 1 at 6:57 AMRedmile Group, LLC Boosts Stake in Neoleukin Therapeutics Incfinance.yahoo.com - July 28 at 11:02 AMMoore Kuehn Encourages AMNB, SCU, NLTX, and PRDS Investors to Contact Law Firmbenzinga.com - July 26 at 7:36 PMAnalysts review Neoleukin Therapeutics Inc.’s ratingknoxdaily.com - July 26 at 7:36 PMALERT: The M&A Class Action Firm Continues Investigating the Merger – SCU, NLTX, HCCI, CCFkentuckytoday.com - July 24 at 11:32 PMBaker Bros. Advisors Now Owns 19.99% of Neoleukin Therapeutics247wallst.com - July 24 at 1:31 PMAn Analysis of Neoleukin Therapeutics Inc. (NLTX)’s Potential Price Growthknoxdaily.com - July 19 at 11:36 AMNeurogene and Neoleukin enter definitive merger agreementpharmabiz.com - July 19 at 6:36 AMNeurogene, Neoleukin Announce Planned Mergermarkets.businessinsider.com - July 19 at 6:36 AMNeurogene, Neoleukin Merging to Advance Gene Therapies for Neurological Diseasesprecisionmedicineonline.com - July 18 at 10:54 PMUniv. of Washington spinout Neoleukin Therapeutics merging with New York City startupmsn.com - July 18 at 5:54 PMNeoleukin Therapeutics, Inc.: Neurogene and Neoleukin Announce Definitive Merger Agreementfinanznachrichten.de - July 18 at 12:53 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBiofronteraNASDAQ:BFRIBiofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.Galera TherapeuticsNASDAQ:GRTXGalera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also developing GC4711, a dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.Iterum TherapeuticsNASDAQ:ITRMIterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.Larimar TherapeuticsNASDAQ:LRMRLarimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.Neoleukin TherapeuticsNASDAQ:NLTXNeoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.